1. Immunotherapy

    Comments Leave a Comment

    1-15 of 213 1 2 3 4 ... 13 14 15 »
    1. Mentioned In 213 Articles

    2. High-Affinity GD2-Specific Car T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

      High-Affinity GD2-Specific Car T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
      ...by an FDA-approved therapeutic monoclonal antibody and is an attractive tumor-associated antigen for cellular immunotherapy. Chimeric antigen receptor (CAR)–modified T cells can have potent antitumor activity in B-cell m...
      Read Full Article
    3. Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in ...

      ...VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk neuroblastoma patie...
      Read Full Article
    4. Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

      ...ease is incredibly encouraging.” Kean first became interested in using abatacept to prevent GvHD based on the immunotherapy drug’s success in treating patients with rheumatoid arthritis. In rheumatoid arthritis, abatacep...
      Read Full Article
    5. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

      ...ith HR-NBL before and following autoHSCT(s). We found that absolute T-, B-, and NK cell counts at the time of immunotherapy were below normal in 80% of patients. Patients with residual disease at the time of transplant h...
      Read Full Article
      Mentions: Immunotherapy
    6. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      ...nta A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN Immunotherapy with short term infusion (STI) of monoclonal anti-GD2 antibody (mAb) ch14.18 (4 × 25mg/m2/d; 8-2...
      Read Full Article
    7. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

      ...mentary KIR/KIR-ligand genotypes, clinical outcome was not significantly different for patients that received immunotherapy vs. those receiving isotretinoin alone. These data show that administration of immunotherapy is ...
      Read Full Article
      Mentions: COG Immunotherapy
    8. 1-15 of 213 1 2 3 4 ... 13 14 15 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Immunotherapy

    1. Our data show that a certain combination of KIR-related genes may be predictive of benefit from immunotherapy.
      In Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy
    2. It has been shown that immunotherapy works for some adult cancers; the question is, what impact will it have on childhood cancers?
      In Combining immunotherapies effective against mouse model of cancer
    3. We believe T-cell immunotherapy has tremendous potential.
      In Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy